Prevalence of Interactions between Dietary Supplements and Oncologic pharmacotherapy in patients with solid tumours
Recruiting
- Conditions
- Patients with solid tumours
- Registration Number
- DRKS00031264
- Lead Sponsor
- Institut für Ernährungsmedizin, Universität zu Lübeck
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 107
Inclusion Criteria
Diagnosis of a solid tumour
outpatient or inpatient oncologic pharmacotherapy
Exclusion Criteria
Dementia comorbidities
Expected life expectancy of < 6 months
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of interactions between dietary supplements and oncological pharmacotherapy (in percent) at the time of oncological therapy
- Secondary Outcome Measures
Name Time Method - Prevalence of interactions between dietary supplements (DS) and oncological pharmacotherapy in DS users<br>- Frequency of need for medical intervention due to detected interactions<br>- Prevalence of interactions between DS and the complete (also non-oncological) medication<br>- Influence of other variables on the occurrence of interactions between DS and oncological pharmacotherapy as well as the complete medication<br>(Age, sex, tumour entity, comorbidities, total number of drugs taken, type and total number of DS taken)<br>- Patients‘ quality of life (using EORTC QLQ-C30 Version 3.0)<br>- Motivation for taking DS